BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Sell
Eagle Pharmaceuticals (NASDAQ:EGRX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.
Other analysts have also issued reports about the stock. TheStreet upgraded shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Thursday, August 9th. Royal Bank of Canada set a $64.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 2nd. Cantor Fitzgerald set a $81.00 price objective on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 24th. ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 31st. Finally, Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Eagle Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $77.17.
Shares of Eagle Pharmaceuticals stock opened at $47.13 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.59 and a quick ratio of 5.38. The stock has a market capitalization of $702.86 million, a P/E ratio of 13.99 and a beta of 1.71. Eagle Pharmaceuticals has a 1 year low of $46.38 and a 1 year high of $85.66.
Large investors have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at about $108,000. Macquarie Group Ltd. increased its stake in Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,200 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Eagle Pharmaceuticals during the 3rd quarter valued at about $115,000. Piedmont Investment Advisors LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $150,000. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at about $156,000.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.